Mesoblast Limited (ASX: MSB)
Health Care · Biotechnology · AU
AU$2.04
-5.56% today · -26.1% 1Y
Mesoblast Limited (ASX: MSB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.84B and employs 108 people.
Over the last twelve months the share price has lost 26.1%, trading between 1.88 and 3.31.
Tweenvest scores Mesoblast Limited across four factors: quality 47/100, value 81/100, growth 100/100. Its strongest factor is growth.
MSB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.84B
- Revenue (TTM)
- $120.25M
- P/E
- —
- EPS
- -0.04
- Dividend yield
- —
- Beta (5Y)
- 0.86
- 52-week high
- AU$3.31
- 52-week low
- AU$1.88
- Avg volume (3M)
- —
- Shares outstanding
- 1.30B
- Employees
- 108
- Next earnings
- —
About Mesoblast Limited
Mesoblast Limited, an Australian enterprise established in Melbourne in 2004, is dedicated to developing innovative regenerative medicine products. The company's global reach extends to the United States, Singapore, the United Kingdom, and Switzerland. Its therapeutic endeavors encompass a wide array of medical conditions, including cardiovascular diseases, spinal and orthopedic ailments, oncology, hematology, and immune-mediated and inflammatory disorders. Mesoblast's distinctive regenerative medicine platform is founded on the therapeutic potential of specialized mesenchymal lineage cells. A prominent candidate, Remestemcel-L, is currently in late-stage (Phase III) clinical trials for various systemic inflammatory conditions, such as steroid-refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic-refractory inflammatory bowel disease. Additionally, Remestemcel-L is undergoing Phase III evaluation for chronic heart failure and chronic low back pain linked to degenerative disc disease. The company's pipeline also features MPC-300-IV, under development for biologic-refractory rheumatoid arthritis and diabetic nephropathy, and MPC-25-IC, aimed at treating or preventing acute myocardial infarction. Mesoblast has forged key strategic partnerships, including one with Tasly Pharmaceutical Group for the commercialization of MPC-150-IM (for heart failure) and MPC-25-IC (for heart attacks) in China. It also collaborates with JCR Pharmaceuticals Co. Ltd. on wound healing therapies for epidermolysis bullosa patients, and with Grünenthal to advance and market a cell therapy for chronic low back pain.
- ISIN
- AU000000MSB8
- Founded
- 2004
- Listed since
- Dec 15, 2004
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Zymeworks Inc.NasdaqGS: ZYME | $1.88B | $25.26 | -4.79% |
| Sarepta Therapeutics, Inc.NasdaqGS: SRPT | $1.85B | $18.21 | +4.06% |
| Xencor, Inc.NasdaqGM: XNCR | $1.85B | $24.50 | -1.37% |
| Zenas BioPharma, Inc.NasdaqGS: ZBIO | $1.84B | $26.24 | -7.26% |
| Pell Bio-Med Technology Co., Ltd.TWSE: 6949 | $1.83B | NT$44.50 | -11.53% |
| Novavax, Inc.NasdaqGS: NVAX | $1.82B | $11.01 | -1.87% |
| Biohaven Ltd.NYSE: BHVN | $1.79B | $11.93 | +0.42% |
| Hualan Biological Vaccine Inc.SZSE: 301207 | $1.78B | CN¥20.11 | +4.25% |
Figures last refreshed Oct 4, 2026.